Blockage of dopaminergic D(2) receptors produces decrease of REM but not of slow wave sleep in rats after REM sleep deprivation

Behavioural Brain Research
Marcelo Meira Santos LimaS Tufik

Abstract

Dopamine (DA) has, as of late, become singled out from the profusion of other neurotransmitters as what could be called a key substance, in the regulation of the sleep-wake states. We have hypothesized that dopaminergic D(2) receptor blockage induced by haloperidol could generate a reduction or even an ablation of rapid eye movement (REM) sleep. Otherwise, the use of the selective D(2) agonist, piribedil, could potentiate REM sleep. Electrophysiological findings demonstrate that D(2) blockage produced a dramatic reduction of REM sleep during the rebound (REB) period after 96 h of REM sleep deprivation (RSD). This reduction of REM sleep was accompanied by an increment in SWS, which is possibly accounted for the observed increase in the sleep efficiency. Conversely, our findings also demonstrate that the administration of piribedil did not generate additional increase of REM sleep. Additionally, D(2) receptors were found down-regulated, in the haloperidol group, after RSD, and subsequently up-regulated after REB group, contrasting to the D(1) down-regulation at the same period. In this sense, the current data indicate a participation of the D(2) receptor for REM sleep regulation and consequently in the REM sleep/SWS balance. Here...Continue Reading

Citations

May 19, 2011·Clinical Neuropharmacology·Aurore GouraudUNKNOWN French Association of Regional Pharmacovigilance Centres
Mar 3, 2015·Expert Opinion on Therapeutic Targets·Frank BellivierJan Scott
Oct 9, 2012·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Claudio BabiloniPaolo Maria Rossini
Apr 28, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Adriano ZagerSergio Tufik
Aug 18, 2010·Bipolar Disorders·Greg Murray, Allison Harvey
Aug 3, 2013·Journal of Neuroscience Research·Ana Carolina D Dos SantosMarcelo M S Lima
Aug 11, 2012·Journal of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan·Hong LvBing Yao
May 18, 2010·Clinical Psychology Review·Allison G HarveyAdriane Soehner
Apr 20, 2016·Neuropharmacology·Adriano D S TargaMarcelo M S Lima
Nov 12, 2013·Neurobiology of Disease·Carole HyacintheImad Ghorayeb
Mar 18, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·A S C FrançaS Ribeiro
Sep 15, 2014·Behavioural Brain Research·Ana Carolina D NosedaMarcelo M S Lima
Jan 13, 2015·Annual Review of Clinical Psychology·Lauren B AlloyElaine M Boland
Sep 29, 2009·Behavioural Brain Research·Takayuki IshidaChiaki Kamei
Sep 24, 2016·Molecular Neurobiology·Patrícia Dos SantosMarcelo M S Lima
Nov 28, 2008·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·C A SantosS Tufik
Jun 26, 2018·Chronobiology International·Julia MaruaniPierre A Geoffroy
Sep 1, 2020·Journal of Sleep Research·Gustavo Zampier Dos Santos LimaMarcelo M S Lima
Mar 16, 2019·Frontiers in Neuroscience·Jelena CiricJasna Saponjic

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Lionel DahanGuy Chouvet
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
Kafui DzirasaMiguel A L Nicolelis
© 2021 Meta ULC. All rights reserved